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Aims Prevention of hospital readmissions is one of the main objectives in the management of patients with heart failure
(HF). Most of the models predicting readmissions are based on data extracted from hospitalized patients rather than
from outpatients. Our objective was to develop a validated score predicting 1-month and 1-year risk of readmission
for worsening of HF in ambulatory patients.
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Methods
and results
A cohort of 2507 ambulatory patients with chronic HF was prospectively followed for a median of 3.3 years. Clinical,
echocardiographic, ECG, and biochemical variables were used in a competing risk regression analysis to construct a
risk score for readmissions due to worsening of HF. Thereafter, the score was externally validated using a different
cohort of 992 patients with chronic HF (MUSIC registry). Predictors of 1-month readmission were the presence
of elevated natriuretic peptides, left ventricular (LV) HF signs, and estimated glomerular filtration rate (eGFR) <60
mL/min/m2. Predictors of 1-year readmission were elevated natriuretic peptides, anaemia, left atrial size >26mm/m2,
heart rate >70 b.p.m., LV HF signs, and eGFR <60 mL/min/m2. The C-statistics for the models were 0.72 and 0.66,
respectively. The cumulative incidence function distinguished low-risk (<1% event rate) and high-risk groups (>5%
event rate) for 1-month HF readmission. Likewise, low-risk (7.8%), intermediate-risk (15.6%) and high-risk groups
(26.1%) were identified for 1-year HF readmission risk. The C-statistics remained consistent after the external
validation (<5% loss of discrimination).
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Conclusion The Redin-SCORE predicts early and late readmission for worsening of HF using proven prognostic variables that
are routinely collected in outpatient management of chronic HF.
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Introduction
Hospital admissions for worsening of heart failure (HF) entail a
huge amount of spending of medical care resources and are pre-
dictive of increased mortality risk.1,2 Thus, health programmes
addressing the management of chronic diseases pursue the pre-
vention of hospital readmissions by establishing appropriate per-
sonalized measures for patients at risk.3
A large number of clinical studies predicting hospitalization for
worsening of HF have been reviewed in detail.4,5 However, these
models have not yet been successfully implemented in current
clinical practice. Most of the available models were constructed
based on administrative and clinical data extracted from hospital
records at patient discharge, thereby not fully reflecting the ambu-
latory clinical condition. On the other hand, many of these studies
reported the overall cause of readmission rather than the specific
cause of hospitalization and, quite often, they had a limited sample
size and the reported study variables were not always routinely
available. An ideal risk model should, among others, overcome
the sample size limitations, use currently available clinical data,
accommodate ongoing variations of the clinical status of outpa-
tients with HF, be validated, and have the potential to discriminate
the ‘high-risk’ patients who will benefit from more intensive thera-
pies from the ‘low-risk’ patients who will be appropriately managed
with less intensive protocols.
This study aimed to develop a validated risk score to predict
short-term (1month) and long-term (1 year) hospitalizations for
worsening of HF in ambulatory patients using precise variables that
are currently collected in primary care practice.
Methods
Study population
This study includes two cohorts of patients. The first one is a deriva-
tion cohort comprised of 2507 patients with chronic HF enrolled in
the Spanish Network for the Study of Heart Failure (REDINSCOR reg-
istry). This is a prospective, longitudinal, multicentre study designed to
assess risk predictors of cardiac mortality and readmissions in ambula-
tory patients with HF.6,7 Patients were consecutively recruited between
January 2007 and January 2011 at HF clinics in 18 hospitals. Inclusion
criteria were: (i) age older than 18 years; (ii) prior hospitalization for HF
(>24 h) during the previous year; and (iii) the presence of at least one
echocardiographic abnormality (LVEF ≤40%, LV end-diastolic diame-
ter ≥60mm, altered LV relaxation indicating diastolic dysfunction, or
thickness of interventricular septum/LV posterior wall ≥14mm). All
patients were symptomatic (functional NYHA class II–IV) and were
treated according to the established clinical guidelines.8 Exclusion cri-
teria were: (i) reversible acute HF; (ii) severe valvular disease amenable
to surgical repair; (iii) right HF secondary to chronic cor pulmonale;
or (iv) concomitant terminal disease. The validation cohort was the
MUSIC (MUerte Súbita en Insuficiencia Cardíaca) study population9
that consisted of 992 ambulatory patients with chronic HF prospec-
tively enrolled from the specialized HF clinics of eight Spanish Uni-
versity Hospitals between April 2003 and December 2004. All these
patients had symptomatic chronic HF (NYHA class II–III) and were
treated according to current guidelines. This study included patients
with either depressed (<45%) or preserved (>45%) LVEF. The latter ..
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.. were included if they had HF symptoms and a prior hospitalization for
HF or some objective signs of HF confirmed by chest X-ray (findings
of pulmonary congestion) and/or echocardiography (abnormal LV fill-
ing pattern and LV hypertrophy). Patients were excluded if they had
recent acute coronary syndrome or severe valvular disease amenable
to surgical repair. Patients with other concomitant diseases expected
to reduce life expectancy were also excluded. Both cohorts complied
with the Declaration of Helsinki, and the protocol was approved by
the ethics committees of each participating centre. All patients gave
written informed consent.
Study variables
Data were collected using specifically designed web forms
(www.redinscor.org), and quality controls were undertaken every
month. We recorded the following clinical variables at study inclusion:
(i) demographic and previous clinical history; (ii) case history and
physical examination; (iii) chest radiography; (iv) ECG; (v) echocar-
diography; (vi) laboratory blood tests; and (vii) medical treatment
(Appendix S1). Standard criteria were used to define each variable.
Anaemia was defined as haemoglobin <120 g/L for women and
<130 g/L for men.10 The plasma levels of NT-proBNP and BNP were
dichotomized for cut-off values of BNP> 43 pmol/L (>150 ng/L) or
NT-proBNP>118 pmol/L (>1000 ng/L), respectively.8 The eGFR was
calculated using the CKD-EPI (Chronic Kidney Disease-Epidemiology
Collaboration) method.11 Left and right ventricular HF signs were
defined according to the Framingham criteria.12 Among them, we have
included paroxysmal nocturnal dyspnoea, rales, orthopnoea, and third
sound gallop as left HF signs, and neck vein distension, hepatojugular
reflux, bilateral ankle oedema, ascitis, and hepatomegaly as right HF
signs.
Follow-up
The follow-up data were obtained from the outpatient visits or from
the event reports. Patients lost to follow-up (none at 1-month and 5 at
1-year) were censored in survival analysis. The reported events were
reviewed by an ad hoc committee.6
Statistical analysis
Continuous variables were expressed as the mean± standard devia-
tion (SD) or as median (interquartile range) whenever appropriate.
Differences in continuous variables were tested by analysis of variance
(ANOVA) or Student’s t-test for independent samples. Categorical
variables are presented as frequency and percentage. Differences in
the categorical variables were assessed by the 𝜒2 test or by Fisher’s
exact test. A multivariate analysis (Fine and Gray regression model)
was built to assess the influence of the different risk predictors on
survival.13 The study endpoint for all regression analyses was the date
of readmission due to HF at 1 month or at 1 year of follow-up. The
competing event was death over the time period. Clinical meaningful
variables showing a significant level in the univariate analysis (P< 0.1)
were thereafter included in the multivariate model. A backward step-
wise method was used to identify independent risk predictors with
P< 0.05 for the inclusion or deletion criterion. We used competing
risk methodology to estimate the probability of HF readmission or
death over a time period of 1 month and 1 year using the cumulative
incidence function (CIF) approach. To analyse the effect of baseline
predictors on the CIF, we used the Fine–Gray regression model for
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics of 2507 outpatients with heart failure in the REDINSCOR registry (derivation
cohort) and 992 outpatients in the MUSIC registry (validation cohort)
REDINSCOR (n= 2507) MUSIC (n= 992) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographic and clinical variables
Male, n 1731 (69.0%) 718 (72.4%) 0.053
Age, years 66.7 (12.9) 64.6 (11.6) <0.0001
Current smoker, n 399 (16.1%) 108 (10.9%) <0.0001
History of dyslipidemia, n 1324 (53.3%) 494 (49.8%) 0.064
Diabetes mellitus, n 1058 (42.4%) 356 (35.9%) <0.001
History of hypertension, n 1700 (68.2%) 565 (57.0%) <0.0001
Prior AMI, n 934 (37.6%) 418 (42.1%) 0.013
Prior CABG or PTCA, n 817 (32.6%) 256 (25.8%) <0.0001
Ischaemic aetiology, n 1192 (47.5%) 453 (45.7%) 0.315
Idiopathic dilated myocardiopathy, n 482 (19.2%) 226 (22.8%) 0.018
Atrial fibrillation/flutter, n 628 (25.1%) 191 (19.2%) <0.001
Prior pacemaker, n 194 (7.7%) 83 (8.4%) 0.537
Prior cardiac resynchronization therapy, n 146 (5.8%) 37 (3.7%) 0.012
Prior implantable cardioverter defibrillator, n 370 (14.8%) 11 (1.1%) <0.001
NYHA class III–IV, n 983 (39.2%) 214 (21.6%) <0.0001
Heart rate, b.p.m. 76.4 (16.5) 71.4 (15.4) <0.0001
Systolic blood pressure, mmHg 121.4 (20.9) 127.0 (21.7) <0.0001
BMI, kg/m2 28.7 (5.1) 28.5 (4.5) 0.255
Framingham left HF signs, n 1387 (56.3%) 336 (33.9%) <0.0001
Framingham right HF signs, n 1077 (44.3%) 223 (23.5%) <0.0001
Radiographic variables
Signs of pulmonary venous hypertension 1053 (52.2%) 169 (17.0%) <0.0001
Cardiothoracic ratio 0.59 (0.08) 0.55 (0.07) <0.0001
Laboratory variables
Haemoglobin, g/L 130.9 (19.9) 137.2 (16.0) <0.0001
Natraemia, mEq/L 139.1 (4.2) 139.2 (3.2) 0.449
eGFR, mL/min/1.73m2 64.3 (24.0) 62.8 (20.4) 0.063
BNP> 43 pmol/L (>150 ng/L) or NT-proBNP> 118 pmol/L (>1000 ng/L) 1320 (67.4%) 379 (43.6%) <0.0001
12-lead ECG variables
QRS duration, ms 123.6 (36.1) 125.5 (35.1) 0.158
LBBB 573 (23.2%) 290 (29.2%) <0.001
RBBB 152 (6.2%) 48 (4.8%) 0.130
Echocardiographic variables
LVEF, % 35.7 (14.6) 36.9 (14.1) 0.028
LV end-diastolic diameter, mm 60.7 (10.7) 61.0 (10.2) 0.453
LA size, mm/m2 25.2 (5.4) 24.6 (4.8) 0.002
Mitral regurgitation III/IV, n 453 (18.5%) 116 (11.7%) <0.0001
Pharmacological treatment
Beta-blocker 1997 (79.8%) 675 (68.0%) <0.0001
Loop diuretics 2119 (84.7%) 698(70.4%) <0.0001
ACE inhibitor or ARB 2124 (84.9%) 861 (86.8%) 0.151
Spironolactone 1108 (44.3%) 372 (37.5%) <0.001
Eplerenone 279 (11.2%) –
Aspirin or clopidogrel 654 (26.1%) 391 (39.4%) <0.0001
Acenocumarol or warfarin 795 (31.8%) 339 (34.2%) 0.172
Statins 1483 (59.2%) 489 (49.3%) <0.0001
Digoxin 572 (22.9%) 298 (30.0%) <0.0001
Amidarone 276 (11.0%) 105 (10.6%) 0.703
Ivabradine 42 (1.7%) –
Qualitative data are presented as absolute frequencies and percentages, and quantitative data as mean± standard deviation.
AMI, acute myocardial infarction; BMI, body mass index; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; HF, heart failure; LA, left atrial;
PTCA, percutaneous transluminal coronary angioplasty RBBB, right bundle branch block.
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Univariable and multivariable predictors of 1-month readmission for worsening of heart failure
Univariable
HR (95% CI)
t P-value Multivariable
HR (95% CI)
𝜷-coefficient t P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Clinical variables
History of dyslipidemia 0.65 (0.42–1.03) 1.84 0.066
NYHA class III–IV 2.00 (1.21–3.31) 2.72 0.007
Heart rate >70 b.p.m. 2.03 (1.17–3.51) 2.52 0.012
Systolic blood pressure 0.98 (0.97–1.00) 2.17 0.030
BMI 0.95 (0.90–1.00) 1.98 0.048
Framingham left HF signs 4.01 (2.21–7.28) 4.58 <0.001 2.79 (1.46–5.33) 1.02 3.09 0.002
Framingham right HF signs 2.49 (1.56–3.96) 3.83 <0.001
Laboratory variables
Anaemia 2.13 (1.36–3.34) 3.30 0.001
Natraemia (>138mEq/L) 0.69 (0.44–1.08) 1.64 0.102
eGFR <60mL/min/1.73m2 2.20 (1.39–3.50) 3.34 0.001 1.87 (1.06–3.30) 0.63 2.16 0.031
BNP> 43 pmol/L (>150 ng/L) or
NT-proBNP> 118 pmol/L (>1000 ng/L)
5.61 (2.25–14.0) 3.70 <0.001 3.95 (1.56–10.03) 1.37 2.89 0.004
Echocardiographic variables
LA size >26mm/m2 1.54 (0.97–2.46) 1.82 0.069
Mitral regurgitation III/IV 1.62 (0.98–2.66) 1.88 0.060
Pharmacological treatment
ACE inhibitor or ARB 0.43 (0.26–0.70) 3.35 0.001
Statins 0.62 (0.40–0.96) 2.12 0.034
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; LA, left atrial.
the subdistribution hazard. The model included only the main effects
of the predictors, without any interaction term. The proportion-
ality assumption of the models was verified using time-dependent
variables. The discriminative ability of the models was assessed by
the C-statistic. The internal validity of the final predictive models
was tested for 500 bootstrap re-samples, using the ‘pec’ package by
Thomas A. Gerds14 in the R Project for Statistical Computing. The
calibration of models was assessed by the corresponding plots using
the same package. To calculate the risk score for 1-month or 1-year
readmission, each final predictor was multiplied by its 𝛽-coefficient
(by 10 for 1-month follow-up and by 13 for 1-year follow-up and
rounded to the nearest integer number). Therefore, the predictors of
a particular patient ranged from 0 to 30. The CIF approach was used
to separate populations of patients into different risk groups. Variables
with >10% of missing data were not included in the models, except
for BNP and NT-proBNP due to clinical relevance. A regression
multiple imputation (n= 5) was applied whenever necessary.15–17 A
two-sided P< 0.05 was considered statistically significant. All analyses
were performed using SPSS (v. 21.0) and STATA (v. 13.1) software.
External validation cohort
As the MUSIC registry did not have a 1-month follow-up visit, we
used a logistic regression analysis with the prognostic variables of the
Redin-SCORE model at 6-month and 1-year follow-up. Accordingly,
using the fitted model, predictions for each subject were used to
calculate the area under the receiver operating characteristic curve
(AUC), which has been considered equivalent to the C-statistic.18 A
loss of <10% of the discriminative ability was accepted. In addition, the
AUCs for both models were compared with the DeLong method19
using the EPIDAT (v. 3.1) software. The calibration of the model
and its ability to allocate patients into the different risk groups were .
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. evaluated by assessing the calibration plot and Hosmer–Lemeshow
test for goodness of fit.
Results
Characteristics of the study population
The REDINSCOR registry included 2507 consecutive outpatients
with chronic HF followed during a median period of 3.3 years. The
clinical characteristics of these patients are summarized in Table 1.
There was a predominance of males (69%), with a mean age of
66.7 years. In nearly half of the cases, the aetiology of HF was
ischaemic heart disease. The mean LVEF was 35.7%, and 39.2%
were in NYHA class III–IV. Preserved LVEF (≥50%) was observed
in 433 patients (17.3%).
The MUSIC registry (external validation cohort) included 992
ambulatory patients with chronic HF followed during a median
period of 3.6 years. As compared with the REDINSCOR cohort,
patients in the MUSIC registry were younger, had fewer cardio-
vascular risk factors, lower incidence of coronary artery bypass
(CABG) surgery, fewer right or left HF signs, and less pulmonary
hypertension and mitral valve regurgitation. They also had better
renal function and lower plasma levels of NT-proBNP.
Hospitalization for worsening of heart
failure
Hospital readmissions for worsening of HF occurred in 78 cases
(3.1%) at 1 month after inclusion and in 424 (16.9%) patients after
1 year of follow-up. The univariable and multivariable predictors of
1-month and 1-year readmission are summarized in Tables 2 and 3.
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Univariable and multivariable predictors of 1-year readmission for worsening of heart failure
Univariable
HR (95% CI)
t P-value Multivariable
HR (95% CI)
𝜷-coefficient t P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Clinical variables
Male 0.76 (0.62–0.92) 2.79 0.005
Age 1.01 (1.01–1.02) 3.53 <0.001
Current smoker 0.75 (0.57–1.00) 1.95 0.051
Diabetes mellitus 1.37 (1.13–1.66) 3.24 0.001
History of hypertension 1.26 (1.02–1.56) 2.13 0.033
NYHA class III–IV 1.73 (1.41–2.13) 5.24 <0.001
Heart rate >70 b.p.m. 1.42 (1.15–1.76) 3.26 0.001 1.37 (1.07–1.75) 0.32 2.52 0.012
Systolic blood pressure 0.99 (0.99–1.00) 2.14 0.032
Framingham left HF signs 2.08 (1.69–2.57) 6.83 <0.001 1.50 (1.18–1.92) 0.41 3.27 0.001
Framingham right HF signs 1.85 (1.53–2.24) 6.26 <0.001
Radiographic variables
Cardiothoracic ratio 10.9 (2.9–40.7) 3.55 <0.001
Signs of pulmonary venous hypertension 1.02 (0.97–1.08) 0.79 0.427
Laboratory variables
Anaemia 1.72 (1.42–2.08) 5.58 <0.001 1.38 (1.10–1.73) 0.32 2.77 0.006
eGFR <60mL/min/1.73m2 1.68 (1.39–2.04) 5.31 <0.001 1.29 (1.03–1.62) 0.25 2.18 0.029
BNP> 43 pmol/L (>150 ng/L) or
NT-proBNP> 118 pmol/L (>1000 ng/L)
2.61 (1.96–3.47) 6.59 <0.001 1.88 (1.39–2.56) 0.63 4.07 <0.001
Echocardiographic variables
LA size >26mm/m2 1.70 (1.40–2.06) 5.39 <0.001 1.42 (1.13–1.78) 0.35 3.02 0.003
Mitral regurgitation III/IV 1.30 (1.03–1.64) 2.21 0.027
Pharmacological treatment
ACE inhibitor or ARB 0.66 (0.52–0.84) 3.43 0.001
Beta-blocker 0.66 (0.53–0.82) 3.75 <0.001
Loop diuretics 2.15 (1.47–3.15) 3.96 <0.001
Eplerenone 0.65 (0.46–0.93) 2.34 0.019
Digoxin 1.30 (1.05–1.61) 2.42 0.015
CI, confidence interval; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; LA, left atrial.
The presence of Framingham left HF signs, eGFR <60mL/min/m2,
and BNP> 43 pmol/L (>150 ng/L) or NT-proBNP> 118 pmol/L
(> 1000 ng/L) were independent predictors for 1-month hospital-
ization in the multivariable analysis. In addition to these variables,
a heart rate >70 b.p.m., the presence of anaemia, and a left atrial
(LA) size >26mm/m2 were independent predictors for 1-year
hospitalization.
In order to build a score able to predict the risk of HF admission
for a given patient, we assigned a scale of 30 points for both a
1-month and a 1-year hospitalization based on the 𝛽-coefficient of
each variable (Table 4). This score allowed the estimation of the risk
of hospitalization for worsening HF, as illustrated in Figure 1. Indeed,
the cumulative incidence function curves distinguished a low-risk
and a high-risk group (<1% and >5% event rate, respectively)
for 1-month HF readmission risk, and low-risk (7.8% event rate),
intermediate-risk (15.6% event rate), and high-risk groups (26.1%
event rate) for 1-year HF readmission.
The C-statistics for the two models were 0.72 and 0.66, respec-
tively. In the preserved LVEF group, the C-statistics were 0.71 and
0.72. After the bootstrap sampling, these indexes were 0.71 and
0.65. The calibration plots of the Fine and Gray models showed
a fairly good calibration for 1-month and 1-year HF readmission
(Figure 2). .
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. External validation
The AUC of the model fitted on the REDINSCOR derivation
sample for 1-month and 1-year HF readmission was 0.73 and 0.67,
respectively. The external validation in the MUSIC cohort showed
an AUC of 0.71 and 0.69 for 6-month and 1-year readmission
models, respectively. Moreover, after comparing the AUCs of both
models, no significant statistical differences were found (P= 0.727
for short-term risk, and P= 0.708 for long-term risk). External
validation of the calibration ability of the 1-year HF readmission
model is illustrated in Figure 3 as a calibration plot, where the
Hosmer–Lemeshow test gave a non-significant P-value.
Discussion
Main findings
This study provides a validated new score that predicts 1-month
and 1-year hospitalization for worsening of HF in ambulatory
patients based on precise variables that are currently assessed
in clinical practice. Moreover, the score allows discrimination
between low- and high-risk patients based on a competing risk
analysis.
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 4 The Redin-SCORE
1 month-HF readmission risk 𝜷-coefficient Adjustment
factor×10 points
Risk
groups
Patients
(n)
Cumulative
incidence
readmission risk (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Framingham left HF signs 1.02 10
eGFR <60mL/min/1.73m2 0.63 6 0–19 points 906 0.9%
BNP>43 pmol/L (>150 ng/L) or
NT-proBNP>118 pmol/L (>1000 ng/L)
1.37 14 20–30 points 1053 5.1%
Total score 30 points
1 year-HF readmission risk 𝛽-coefficient Adjustment
factor× 13 points
Risk groups Patients (n) Cumulative incidence
readmission risk (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Framingham left HF signs 0.41 5
Heart rate >70 b.p.m. 0.32 4
Anemia 0.32 4 0–12 points 641 7.8%
BNP> 43 pmol/L (>150 ng/L) or
NT-proBNP> 118 pmol/L (>1000 ng/L)
0.63 8 13–20 points 562 15.6%
eGFR <60mL/min/1.73m2 0.25 4 21–30 points 756 26.1%
LA size >26mm/m2 0.35 5
Total score 30 points
eGFR, estimated glomerular filtration rate; HF, heart failure; LA, left atrial.
Previous studies
Several studies have reported predictive models of hospitalization
in HF patients.20 The benefits of identifying HF patients needing
a more personalized care are fully recognized, but predictive
models of HF hospitalization are far from being implemented in
current clinical practice. Factors limiting the predictive power
of the available studies have been recently reviewed in detail.4,5
Chief among the limitations are their lower C-statistic values as
compared with those found in mortality models,21,22 and, on the
other hand, hospitalization may greatly depend on quality of care
and health system characteristics rather than on the patient’s
clinical condition itself. Moreover, the analysed variables were
largely heterogeneous among the studies and were not always
validated. Quite often data were extracted from retrospective
administrative data21 or from inpatient clinical registries,22–25 and
were rarely obtained from ambulatory HF patients. Therefore,
the validation and performance of these tools have not been
established in outpatients. In several instances, the scores have
been developed based on data from clinical trials,26–28 and this
scenario might be far removed from real-life daily practice.
Recently, investigators from the University of Michigan have pro-
posed the HFPSI score (Heart Failure Patient Severity Index) to
predict the 6-month risk of death and/or all-cause medical hospi-
talization in HF outpatients.29 Using multivariable Cox modelling
in a cohort of 1536 patients, the HFPSI included blood urea
nitrogen (BUN), BNP, diabetes, history of atrial fibrillation/flutter,
NYHA class, and all-cause hospitalization within the 6 months.
Kaplan–Meier curves distinguished between a low-risk group (8%
even rate) and a high-risk group (57%). The C-statistics were 0.71
and 0.68 in the validated Ann Arbor Veterans’ Affairs cohort. Of
note, this study only reported all-cause hospitalization, but not spe-
cific causes of HF admissions. ..
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. Two of the former clinical prediction tools were derived from
the trial Candesartan in Heart Failure: Assessment of Reduction in
Mortality and morbidity (CHARM)28 and the Seattle Heart Failure
Model.30 The CHARM trial evaluated all-cause mortality and the
combined outcome of cardiovascular death and HF hospitalization
over a 2-year period, leading to a C-statistic of 0.75. The way
to calculate the CHARM score is complex because it requires
fulfilling up to 24 variables. On the other hand, the model does
not include data on blood laboratory tests, and the study was
conducted as a clinical trial with a selected non-real-life population
of HF patients. Finally, the CHARM model predicts a combined
event that has different clinical implications. The widely validated
Seattle Heart Failure Model looked at mortality risk in ambulatory
HF patients with LVEF <30%.
Likewise, investigators of the HF-ACTION trial have developed
a multivariable model predicting a combined endpoint (death
and all-cause admission) with a C-index of 0.63 in outpatients
with chronic HF and LVEF <35%, using patient data at the time
of initial presentation from this trial.31 As potential limitations,
these authors indicated: exclusion of preserved LVEF, lack of
natriuretic peptide data, and no external validation. Investigators
of the CORONA trial built a series of models for several out-
comes, including admission for worsening of HF. They proved
the incremental prognostic value of adding biomarkers such
as high-sensitivity C-reactive peptide and NT-proBNP.32 All
ambulatory patients from the CORONA trial had an ischaemic
aetiology, and several biochemical parameters such as sodium or
haemoglobin were not available. Moreover, these data were not
validated in an external cohort.
Thus, nowadays there is a lack of available scores allowing the
prediction of which ambulatory patients are at risk of hospitaliza-
tion for worsening of HF in our current clinical practice.
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Cumulative incidence curves of hospitalizations risk for worsening of heart failure in the REDINSCOR cohort after 1-month (upper
panel) and 1-year (lower panel) follow-up.
Considerations on the Redin-SCORE
The Redin-SCORE is an easy, simple tool able to stratify the
short- and long-term risk of admission for worsening of HF. It
only requires from three to six clinically precise variables. This
score has been constructed from a large multicentre registry,
with a broad spectrum of integrative information (clinical history,
physical exam, ECG, blood test, echo data, treatment) that is
easily available in daily clinical practice. The variables conform-
ing the Redin-SCORE model were not chosen by chance because
they share pathophysiology plausibility. Indeed, our risk predictors
are indicators of some of the pathophysiological derangements
present in HF syndrome: volume overload (Framingham left HF .
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.. signs, BNP, or NT-proBNP), deleterious compensatory mecha-
nisms (heart rate), target organ damage (anaemia, eGFR), and car-
diac remodelling (LA size). Moreover, the predictors found in our
study have been previously reported as prognostic markers of HF
outcome.
The Redin-SCORE identifies high-risk groups of HF patients
prone to be admitted within the short term (>5% rate) or long
term (nearly 30% rate) and has been validated in a different
population of HF patients (MUSIC cohort) with a robust result.
In the outpatient environment, this score should provide the
opportunity to identify those patients requiring care management
programmes at specific HF clinics. Home visiting programmes and
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Calibration plot of the 1-month (upper panel) and 1-year (lower panel) hospitalization Fine–Gray regression models for worsening
of heart failure.
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Figure 3 Calibration plot of the 1-year hospitalization model
for worsening of heart failure (external validation).
specialized HF units are nowadays the most efficient means of
reducing all-cause admissions (and even mortality) for chronic HF
patients.33
Although the Redin-SCORE includes a wide range of rele-
vant variables of HF, the REDINSCOR registry did not collect
specific information about co-morbidities or psychosocial fac-
tors. As mentioned in the Methods section, the MUSIC reg-
istry did not have a 1-month follow-up visit, and therefore we
used a logistic regression analysis with the prognostic variables
at 6-month and 1-year follow-up. Both the study and validation
cohorts comprised patients from the same geographic area, and
thus our model would need further validation in other coun-
tries. Finally, some admissions may be missing if they occurred
in non-REDINSCOR centres. However, the Spanish Health Sys-
tem assigns a geographic distribution of medical resources for
each patient, and thus losses will not be significant. The inci-
dence of hospitalization for worsening of HF of ∼17% in our study
was apparently low in comparison with those reported in previ-
ous publications.4,5 However, studies reporting higher hospitaliza-
tion rates include all-cause hospitalization and often they included
patients with acute rather than ambulatory chronic HF. Lastly, the
percentages of second-line therapies such as CRT and defibrilla-
tors were low, so we have not been able to analyse their probable
prognostic role.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
Appendix S1. List of REDINSCOR variables.
Appendix S2. The investigators of the Spanish Heart Failure
Network (REDINSCOR).
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